Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The study is an open-label study in adults with primary sclerosing cholangitis to evaluate
the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.